Sareum Holdings plc (SAR) ORD GBP0.0125

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Sareum progresses Covid-19 and autoimmune treatment candidate
16 March 2022 14:21
(Sharecast News) - Specialist drug developer Sareum Holdings updated the market on the development of its 'SDC-1801' - a potential Covid-19 and autoimmune disease treatment - towards first-in-human...
-
Sareum expects FY losses to widen on higher R&D costs, supply delays
19 August 2021 07:41
(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.
-
Sareum positive on SRA737 outlook after Sierra call
6 August 2021 15:00
(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced...
-
Sareum releases 'encouraging' results from Covid-19 research
1 July 2021 11:18
(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.
-
Sareum's pre-clinical development of SDC-1801 delayed by Covid-19
25 May 2021 10:56
(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801...
-
Sareum gets approval for US patent application
7 January 2021 12:52
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office has now formally approved its patent application, number 16/351,620.
-
Sareum Holdings secures grant for Covid-19 treatment project
3 December 2020 12:19
(Sharecast News) - Specialist drug development company Sareum Holdings announced on Thursday that the grant offer letter from UK Research and Innovation (UKRI) had now been received and approved.
-
Sareum gets conditional approval for UKRI grant
27 October 2020 08:21
(Sharecast News) - Specialist drug development company Sareum Holdings announced on Tuesday that its application for a grant of around £0.17m from UK Research and Innovation (UKRI) to investigate the...
-
Sareum to get US patent on SDC-1802 programme
8 October 2020 15:50
(Sharecast News) - Specialist drug development company Sareum announced on Thursday that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent on an invention...
-
Sareum Holdings upbeat ahead of cancer research presentation
27 September 2019 09:10
(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Friday that it will present new preclinical data from its 'SDC-1802 TYK2/JAK1' inhibitor cancer...
-
Sareum Holdings expects broadly flat interim losses
27 August 2019 08:35
(Sharecast News) - Drug developer Sareum expects interim losses to be broadly flat year-on-year as it continues to focus on the development of multiple treatments for cancer and autoimmune diseases.
Company announcements Announcements
-
Sareum to Present at BioTrinity 2022 Conference
26 April 2022 07:00
Sareum Holdings
-
Sareum notes acquisition of Sierra Oncology by GSK
13 April 2022 16:00
Sareum Holdings
-
Second Price Monitoring Extn
13 April 2022 11:05
Sareum Holdings
-
Price Monitoring Extension
13 April 2022 11:00
Sareum Holdings
-
European Patent Granted for Sareum’s SDC-1802
11 April 2022 07:00
Sareum Holdings
-
Second Price Monitoring Extn
8 April 2022 16:41
Sareum Holdings
-
Price Monitoring Extension
8 April 2022 16:36
Sareum Holdings
-
Second Price Monitoring Extn
6 April 2022 14:06
Sareum Holdings
-
Price Monitoring Extension
6 April 2022 14:00
Sareum Holdings
-
SDC-1801: Preclinical Toxicology Report Received
16 March 2022 07:00
Sareum Holdings
-
Second Price Monitoring Extn
9 March 2022 11:06
Sareum Holdings
-
Price Monitoring Extension
9 March 2022 11:00
Sareum Holdings
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.